<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">3067</id>
  <title>T3D3025</title>
  <common-name>Ketamine</common-name>
  <description>Ketamine is only found in individuals that have used or taken this drug. It is a cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] Ketamine has several clinically useful properties, including analgesia and less cardiorespiratory depressant effects than other anaesthetic agents, it also causes some stimulation of the cardiocascular system. Ketamine has been reported to produce general as well as local anaesthesia. It interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.</description>
  <cas>6740-88-1</cas>
  <pubchem-id>3821</pubchem-id>
  <chemical-formula>C13H16ClNO</chemical-formula>
  <weight>237.092040</weight>
  <appearance>White powder.</appearance>
  <melting-point>92-93°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>4.64e-02 g/L</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Rapidly absorbed following parenteral administration.</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Ketamine has several clinically useful properties, including analgesia and less cardiorespiratory depressant effects than other anaesthetic agents, it also causes some stimulation of the cardiocascular system. Ketamine has been reported to produce general as well as local anaesthesia. It interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.</mechanism-of-toxicity>
  <metabolism>Hepatic.Half Life: 2.5-3 hours.</metabolism>
  <toxicity></toxicity>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Ketamine is primarily used for the induction and maintenance of general anesthesia, usually in combination with some sedative drug. Other uses include sedation in intensive care, analgesia (particularly in emergency medicine), and treatment of bronchospasm. It is also a popular anesthetic in veterinary medicine. [Wikipedia] For use as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Chronic use of ketamine may lead to cognitive impairments including memory problems. [Wikipedia]</health-effects>
  <symptoms>Ketamine has a wide range of effects in humans, including analgesia, anesthesia, hallucinations, elevated blood pressure, and bronchodilation.[Wikipedia]</symptoms>
  <treatment>Supportive ventilation should be employed. Mechanical support of respiration is preferred to administration of analeptics. (L1712)</treatment>
  <created-at type="dateTime">2009-07-21T20:28:40Z</created-at>
  <updated-at type="dateTime">2014-12-24T20:25:56Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Ketamine</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C07525</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>6121</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Ketamine</stitch-id>
  <drugbank-id>DB01221</drugbank-id>
  <pdb-id></pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CNC1(CCCCC1=O)C1=CC=CC=C1Cl</moldb-smiles>
  <moldb-formula>C13H16ClNO</moldb-formula>
  <moldb-inchi>InChI=1/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3</moldb-inchi>
  <moldb-inchikey>InChIKey=YQEZLKZALYSWHR-UHFFFAOYNA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">237.725</moldb-average-mass>
  <moldb-mono-mass type="decimal">237.092041846</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>2.9</logp>
  <hmdb-id>HMDB15352</hmdb-id>
  <chembl-id>CHEMBL742</chembl-id>
  <chemspider-id>3689</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;John A. Flores, Kenton L. Crowley, &amp;#8220;Process for the preparation of ketamine ointment.&amp;#8221; U.S. Patent US5817699, issued June, 1995.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
</compound>
